Most clinical-stage companies ask the same question about their first Chief Medical Officer: when should we hire one? It is the right question asked in the wrong order. The better starting point is which decisions will need medical leadership in the next eighteen months, and who is making them today.
In many early companies, those decisions sit with a scientific founder, a board member with clinical experience, or a consultant who joined for the pre-IND meeting and never quite left. That arrangement can work for longer than people expect. It stops working when clinical choices start to carry consequences that are expensive to reverse.
Signals that the role has become urgent
No single milestone triggers the hire. There is usually a cluster of signals, and when several appear together, the cost of waiting begins to exceed the cost of the salary.
- IND-enabling studies are underway and the first-in-human protocol is being drafted, including dose escalation design, starting dose rationale, and patient population.
- Your next financing depends on a clinical narrative that investors will test with their own medical advisors.
- You are preparing for a pre-IND meeting and need someone who can own the conversation with FDA, not simply attend it.
- Indication selection is still open, and the choice will shape trial design, competitive position, and the commercial story for years.
- A CRO is being selected and nobody internal has the standing to hold it accountable on medical decisions.
If none of these apply, a strong clinical consultant may serve you better. If most of them apply and no search has started, you are likely already late. A careful CMO search often takes several months from kickoff to start date, and the protocol will not wait.
Three profiles that carry the same title
The CMO title covers very different jobs. Before writing a specification, decide which of these your company needs most right now.
The drug developer has taken assets from preclinical work into early clinical trials, understands how a clinical development plan connects to regulatory strategy, and has sat across the table from FDA. This is the most common need for a company approaching its first IND or Phase 1 study.
The therapeutic area authority brings deep clinical expertise and relationships with key opinion leaders and investigators. This profile matters most when site selection, enrollment, and scientific credibility in a narrow field are the binding constraints, as they often are in rare disease or specialized oncology.
The question is not whether a candidate is impressive. It is whether their best work happened at the stage you are about to enter.
The late-stage operator knows pivotal trials, safety databases, and the path to an NDA or BLA. That experience is valuable, but it is often premature for a company still finalizing a first-in-human protocol, and it is usually priced accordingly.
The question is not whether a candidate is impressive. It is whether their best work happened at the stage you are about to enter. Many strong candidates combine two of these profiles. Few combine all three, and a specification that demands all three will either stall the search or reward the candidate who interviews best rather than the one who fits.
Interim, fractional, or full-time
Not every company needs a full-time CMO on day one. A fractional or interim medical leader can author the clinical development plan, lead the pre-IND interaction, and help select the CRO. This preserves runway and buys time to define the permanent role with more clarity.
The tradeoffs are real. Fractional leaders divide their attention across companies, and investigators and investors notice the difference between a medical lead who is present and one who visits. Interim arrangements also tend to outlast their intended term. If you take this route, set a defined scope, a clear end date, and an explicit plan for the transition to a permanent hire.
A full-time hire makes sense when the company has the capital to support the role through at least one meaningful clinical readout, and when the medical leader will be a visible part of how investors, partners, and future employees understand the company.
Define the role before the search begins
The most common failure in first-CMO searches happens before any candidate is contacted. The board and the CEO hold different pictures of the role, and those differences surface late, usually in final interviews or during offer negotiation.
Align on a few points first: who the CMO reports to, whether they will have board-facing responsibility, how decision rights are divided with the CEO and the head of research, and which clinical decisions they will own outright. Agree on what success looks like at twelve and twenty-four months, framed around decisions and milestones rather than activity.
Then look at the team the CMO will inherit or need to build. A first CMO without clinical operations, regulatory, or program management support will spend the first year doing three jobs, and the strongest candidates will ask about this early. Have a credible answer ready.
Hiring a first CMO is one of the clearest statements a company makes about the kind of developer it intends to become. That statement deserves to be made deliberately.
